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Abstract
The hyper-IgM (HIGM) syndromes are a group of molecular defects of immunoglobulins class 
switch during B cell maturation. In HIGMs the level of IgM is elevated in majority of cases but also can 
by in normal range or even decreased. The other class of immunoglobulins are decreased or absent. The 
five types of HIGM are known: one X-linked (T lymphocyte defect) and four (including B cell defects) 
transmitted in the autosomal recessive pattern.
The 4 cases of HIGM are shown: 3 boys diagnosed at age of 1, 6 and 15 years and one girl with 
DiGeorge syndrome and HIGM developed at age 4. In 2 cases the haematological symptoms (thrombo-
cytopenia and neutropenia) were observed. The expression of CD40L on activated T lymphocytes was 
present in all patients but the level of expression was different. The low level of CD40L was associated 
with early onset and severe course of infections. All patients are treated with intravenous IgG substitu-
tion what resulted in decrease the frequency and severity of infections. 
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Introduction
The hyper-IgM syndrome (HIGM) is a heterogeneous 
group of antibody production disorders comprising 5 types. 
The first X-linked form (HIGM1) is caused by mutation in 
the gene encoding of CD40 ligand (CD40L). The others 
transmitted in autosomal recessive pattern are concerned 
with mutations in the genes encoding the activation-induced 
cytidine deaminase (HIGM2), CD40 (HIGM3) or uracil-N 
glycosylase (UNG deficiency – HIGM5). The most frequ-
ent autosomal recessive HIGM (HIGM4) has no defined 
molecular basis but the defect probably affects the DNA 
repair mechanism [1-10]. 
The CD40L (CD154) is a transmembrane protein type 
II belonging to TNF (tumour necrosis factor) superfamily. 
CD40L is predominantly expressed on mature, activated T 
lymphocytes, monocytes and NK cells. CD40 belongs to 
the same superfamily of TNF proteins and constitutively 
expressed on precursors and mature B-cells, macropha-
ges/monocytes, dendritic cells, vascular endothelial cells 
and epithelial cells. CD40L binding to extracellular do-
mains of CD40 induces interaction of TNF receptor asso-
ciated proteins (TRAF) with the intracellular domains of 
CD40. The activation of this pathway leads to switch of 
the immunoglobulins isotype. Moreover, the interaction of 
CD40L/CD40 on the surface of B cell provides an essen-
tial signal for antibody production, affinity maturation and 
germinal centre formation in lymph nodes and rescues of 
B cells from apoptosis at some stages of differentiation [2, 
3, 5, 7, 11, 12]. 
The patients with HIGM1 are unable to develop the ef-
fective T cell-dependent antibody response what results in 
high susceptibility to bacterial infections. These patients are 
also susceptible to infections caused by intracellular opportu-
nistic pathogens such as Pneumocystis carini, Cryptospori-
dium parvum and many other. Defective CD40L/CD40 inte-
raction also leads to defective T cell/monocytes co-operation 
and an abnormal cellular response. Ineffective interaction 
between T cell and antigen-presenting cells (APC) expres-
sing CD40 resulted in low or absent of stimulation of the 
production of Interleukin-12 (IL-12) [7, 13]. 
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Table 1. The patients’ characteristics
Patient 1 Patient 2 Patient 3 Patient 4
age at diagnosis, gender 7 months, boy 5 years, boy 15 years, boy 4 years, girl
immunological tests
immunoglobulins
IgG (g/L)
IgA (g/L)
IgM (g/L)
2.07
<0.05
1.47
1.03
<0.07
2.12
0.09
0.1
21.90
<1.0
<0.05
40.0
4.59
0.36
6.44
lymphocytes T
CD3 (%)
CD4 (%)
CD8 (%)
T α/β (%) 
T γ/δ (%) 
CD3/HLA-DR (%)
39
29
10
20
1
ND
83
63
20
ND
ND
15
82
34
44
ND
ND
ND
71
29
37
60
7
11
53
41
12
ND
ND
ND
lymphocytes B: CD19 (%) 54 6 8 12 41
NK (%)  8 8 ND 12 ND
adhesion molecules
CD11a  (%)
CD18  (%)
CD154 (CD40L) (%)
CD40 (%)
77
89
24
100
ND
ND
ND
ND
ND
ND
90
98
ND
ND
93.3
99
ND
ND
88
98.5
mitogen response (stimulation index)
Nil (cpm)
PHA (cpm) (IS)
ConA or CD3 (cpm) (IS)
PWM (cpm) (IS)
1174
40694 (34)
57095 (48)
40848 (34)
2160
3422 (1)
27793 (12)
70303 (32)
756
61190 (80)
30511 (40)
21448 (28)
465
1173 (2)
 752 (1)
641 (1)
628
40520 (64)
34003 (54)
28064 (44)
Bacterial infections are the main clinical symptoms ob-
served in all types of HIGM. The majority of HIGM patients 
demonstrate bacterial infections of lungs and the infections 
of upper respiratory tract including sinusitis and recurrent 
otitis. In severe clinical form of HIGM the infections inclu-
ding viral (cytomegalovirus, adenovirus), mycobacterial pa-
thogens and Pneumocystis carini pneumonia are observed 
early, in first year of life. The chronic diarrhea following the 
infection with Cryptosporidium species, Gardia lamblia, 
Salmonella, Entamoeba histolytica and others pathogens 
occurs in more than half of HIGM patients. The reasonable 
number of them requires total parenteral nutrition because 
of malnutrition syndrome. The life threatening infections of 
the central nervous system, chronic infections of liver or 
sepsis are less frequent. The cholangitis sclerotisans caused 
by different pathogens including Cryptosporidium leads to 
liver cirrhosis or malignancy what is the most serious com-
plications of HIGM1 [5-7]. Patients with HIGM, particular-
ly HIGM1 type, develop the haematological abnormalities 
such as persistent or cyclic neutropenia [5, 7]. Anaemia is 
observed in about quarter of HIGM patients and is asso-
ciated with chronic infections, autoimmune mechanisms 
and bone marrow insufficiency. The lymphoid hyperplasia 
and splenomegaly are associated with infections particular-
ly with persistent or recurrent forms. These symptoms are 
frequently noted in HIGM patients during severe infections. 
The persistent lymph nodes enlargement requires investiga-
tion including possibility of malignancy as HIGM patients 
have high risk of lymphoproliferation [6, 7]. 
The aim of this study is to present 4 patients with HIGM 
demonstrating the heterogeneous clinical features of this 
immunodeficiency. The results of immunological assays at 
diagnosis and the expression of CD40L on activated T cells 
and CD40 on B cells are discussed. The clinical course of 
disease and the results of the IVIG therapy are presented. 
Patient 1
The boy was born as a full-term, healthy, fourth child 
in non-consanguineous couple. The siblings of patient are 
healthy without symptoms of immunological defects. The 
patient was admitted to hospital at age of 6 months for the 
first time with severe interstitial pneumonia and pneumo-
thorax. The examination of fluid specimens from pulmo-
nary drainage of right lung showed Pneumocystis carini 
infection. The therapy with antibiotics, pentamidine, sul-
phonamides, and steroids was only a partially effective. He 
was ventilated mechanically and feeded parenteraly. The 
blood tests showed neutropenia, anaemia. The level of IgG 
and IgA were decreased and the level of IgM was within 
normal range. The number of T lymphocytes was decreased 
but B lymphocytes was increased (table 1). The bone mar-
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row aspiration showed decreased percentage of precursors 
and mature myeloid cells. In analysis of immunophenotype 
the increased percentage of B cell precursors was detected 
within the lymphoid cell population. The substitution with 
intravenous immunoglobulin IgG (IVIG) and granulocyte 
colony stimulating factor (G-CSF) was added to symptoma-
tic therapy including antibiotics and bronchodilatators. The 
symptoms of respiratory insufficiency slowly resolved upon 
this therapy. After 7 months the boy was discharged from 
hospital with following therapy: sulphonamides, IVIG, spa-
smolytics and G-CSF.
After one year the boy was re-admitted with pneumo-
nia and respiratory insufficiency. The standard therapy 
with antibiotics, steroid and spasmolytics was ineffective 
and patient developed ARDS. He required the mechanical 
ventilation for one month. The chest X-ray demonstrated 
inflammation of lungs and pneumothorax, bronchiectases 
and dense foci recognised as lung fibrosis. In blood tests 
the severe neutropenia (below 500 neutrophils per µL), ana-
emia, low level of IgG and IgA were noted. Despite of the-
rapy (IVIG, G-CSF, antibiotics) the sepsis with Staphylo-
coccus epidermidis developed and was successfully treated. 
The slow resolution of clinical symptoms was noted and the 
boy was discharged from hospital after 6 months with the 
diagnosis of hyper IgM syndrome. 
The maintenance therapy included sulphonamides, 
substitution of IVIG (0.4 g/kg b.w. once per month) and 
G-CSF daily. The following episodes of pneumonia were 
observed 2 years later but the clinical course was less seve-
re. In outpatient observation the neutropenia was persistent 
(500-800 neutrophils per µL) despite of G-CSF injections 
but the infections were rare and mild in the course. A longi-
tudinal monitoring of immunoglobulins level during IVIG 
therapy showed Ig level within normal range for age, IgA 
deficiency and low or normal level of IgM. There was no 
increase of IgM during 4 years of follow-up observation (fi-
gure 1) but in the present year the increase of IgM was no-
ted despite of IVIG regular substitution. Now, the boy is in 
a good state, slightly underweight and underheight with the 
substitution of IVIG in every 4 weeks, G-CSF and sulpho-
namides as permanent therapy. Auscultation of the lungs 
reveals the crepitations what corresponds to the stationary 
phase of pulmonary fibrosis. Patient is under physical and 
symptomatic therapy improving respiration.
The initial diagnosis was hypogammaglobulinemia but 
after analysis of clinical course and results immunological 
tests (decrease of IgG, low expression of CD40L) the dia-
gnosis was described as HIGM syndrome. 
Patient 2
The boy with no history of previous severe infections 
was admitted to hospital at age 5 years with symptoms of 
bronchopneumonia, hepatosplenomegaly and lymphadeno-
pathy. In X-ray of chest the enlargement of lymph nodes 
in mediastinum, disseminated inflammatory infiltrations in 
both lungs. The laboratory tests showed high ESR, increased 
leukocyte count. Serological tests were negative for CMV 
(both IgG and IgM), negative for Mycoplasma pneumoniae 
(both IgG and IgM) and positive for Toxoplasma gondi in 
IgM class only. The therapy with antibiotics (biofuroxym, 
biodacine, rovamycin) and metronidazole was successful. 
A month later the patient was re-admitted to hospital becau-
se of lymphadenitis. The sulphonamides were used with im-
provement of clinical symptoms. He was again hospitalised 
after following 5 months with symptoms of severe pneu-
monia and pleuritis. In laboratory tests ESR, LDH and CRP 
were markedly increased. The assay of immunoglobulins’ 
level showed the trace of IgG, deficiency of IgA, and the 
increase of IgM level (table 1). After therapy with antibio-
tics the clinical symptoms improved. The IVIG therapy has 
been applied with decrease of IgM level (figure 1). Since 
the last pneumonia the patient is in a good state without 
symptoms of infection. The lymph nodes in maxillary and 
neck region are enlarged. The chest X-ray showed no rema-
ining changes after previous pneumonias (bronchiectases, 
fibrosis) and no mediastinal lymphadenopathy. The patient 
remains under regular substitution of IVIG in every 4 weeks 
in outpatient system. In last year the trimetoprim was instal-
led as anti-Pneumocystis prophylaxis.
Relatively mild clinical course in this case of HIGM 
may be associated with inducible expression of CD154. The 
lymphadenopathy noted in this case is a typical symptom 
noted in about half of HIGM patients [2, 5, 7].
Patient 3
The boy was born as a full-term healthy child in a fami-
ly without previous history of immunodeficiency. He has 
a healthy, younger sister.
Fig. 1. The follow-up of IgM level in serum before (the first 
data) and during the IVIG therapy in cases 1-3 of HIGM pa-
tients. The assay was performed 3-4 times per year in a day of 
IgG substitution before IVIG administration
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Patient did not develop any symptoms of immunodefi-
ciency during the first 8 years of life. The bacterial pneumo-
nia at age 9 years was the first severe infection. The chest 
X-ray showed involvement of right upper lobe. The antibio-
tic therapy was successful, but one year after the recurrent 
pneumonia localised within the same right lung lobe was 
observed. Laboratory tests revealed antibodies against My-
coplasma pneumoniae but only in IgM class (titre 1:100). 
The therapy with antibiotics (amoxicillin, amikacin, clarith-
romycin and cefuroxim) was effective. 
The subsequent pneumonia was noted 2 years later and 
the inflammatory infiltrations were observed in both lungs. 
The clinical symptoms were severe and the patient required 
steroids in addition to antibiotics (tarcefoxim, roxitromycin). 
The symptoms resolved upon this therapy. After 4 months 
the patient was readmitted to hospital with the sinusitis and 
pyelonephritis. The therapy with antibiotics, steroids and 
spasmolytics was introduced with good response. Up at age 
of 15 years the next bronchopneumonia was diagnosed with 
Staphylococcus haemolyticus (MRSE) detected in the blo-
od culture. The immunological tests were performed during 
this infection for the first time. The very high level of IgM, 
a trace of IgG and lack of IgA were detected (table 1). The 
therapy with antibiotics and intravenous immunoglobulins 
(IVIG – 0.4 g/kg b.w.) resulted in clinical improvement. 
The decrease of IgM was observed but the level remained 
above the normal range. From the first IVIG substitution the 
boy remains with no symptoms of infections. The results of 
laboratory tests (ESR, CRP, blood test or urine) are within 
normal range. The follow-up of IgM level under IVIG sub-
stitution is shown on figure 1.
In this case the proper diagnosis of HIGM was delayed 
because of asymptomatic course of disease during the first 
8 years of life. The extremely high level of IgM, lack of IgG 
and IgA suggested HIGM. 
Patient 4
The girl was born as third child in family without pre-
vious history of immunodeficiency. The two sisters are he-
althy. She was born with clinical symptoms of DiGeorge’ 
anomaly (hypocalcemic episodes, congenital heart disease). 
The diagnosis of DiGeorge syndrome was genetically pro-
ved. The results of immunological test of cellular immunity 
are shown in table 2. The cardiac surgery for Fallot’s tetra-
logy was successfully performed at age of 6 months. In the 
next 6 months of life she suffered from recurrent pneumo-
nias (3 times). The levels of IgG and IgA were decreased 
but the level of IgM was within normal range. At age of 
2 years the severe thrombocytopenia, neutropenia occurred. 
The therapy included regular IVIG (0.4 g/kg b.w.) substitu-
tion, administration of steroids and thymus-derived factor. 
After 6 months the side effects of steroids and the recur-
rence of episodes of severe thrombocytopenia (below 5000 
platelets per µL) were an indication for immunosuppression 
(azathioprine in standard dose). The control of immunglo-
bulins level in this time showed the increase of IgM level 
(table 1). The systematic increase of IgM level was obse-
rved during next 2 years of follow up (figure 2) despite of 
regular IVIG substitution. Till now, the chronic, therapy re-
sistant thrombocytopenia, recurrent infections of upper re-
spiratory tract and splenomegaly are the main problems of 
this patient. The maintenance therapy includes low dose of 
steroids, azathioprine, thymic factors, bronchodilatators and 
IVIG substitution. The severe haemolytic anaemia episode 
(January 2006) was noted during IVIG substitution so the 
immunoglobulins substitution was cancelled for 6 months. 
After high-dose steroid therapy the enlargement of spleen 
diminished and the suggested splenectomy was postponed. 
Now, the substitution was administered again because of 
upper respiratory tract infections. The level of IgM is still 
Table 2. Case 4 – the results of immunological tests for cellular immunity
Date 02.01.2003 18.03.2003 25.11.2003 26.02.2004 21.09.2004 27.07.2006 29.06.2006
T cell subpopulations
CD3 – % (/µL) 
CD4 – % (/µL)
CD8 – % (/µL)
CD3/HLA-DR
53(ND)
 41 (ND)
12 (ND)
ND
60 (ND)
46 (ND)
15 (ND)
17 (ND)
64 (ND)
52 (ND)
14 (ND)
ND
82 (1804)
70 (1540)
11 (242)
ND
78 (2262)
61 (1769)
16 (464)
ND
86 (1118)
70 (910)
15 (195)
ND
80 (1600)
61 (1220) 
19 (380)
ND
B cell number
% (/µL) 11 (ND) 15 (ND) 14 (ND) 7 (156) 5 (145) 4 (52) 4 (80)
stimulation response
Nil cpm
PHA cpm (S.I.)
CD3
PWM
Nil
PPD
Candida albicans
628
40520 (64)
34003 (54)
28064 (44)
ND
ND
ND
3006
15865 (5)
14272 (4)
9622 (3)
ND
ND
ND
568
21452 (37)
7051 (12)
4392 (7)
ND
ND
ND
1972
42883 (22)
37924 (19)
11935 (6)
ND
ND
ND
634
561 (1)
733 (1)
677 (1)
354
602 (1)
360 (1)
362 (1)
ND
ND
ND
516
469 (1)
447 (1)
384 (1)
220
264 (1)
224 (1)
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high (range 15 g/l – 30 g/l) with no association with clinical 
state or symptomatic and steroid therapy. The electropho-
resis of IgM showed polyclonal IgM. The elevated IgM 
or secondary HIGM was diagnosed based on immunolo-
gical results. The level of IgM in this patient is “resistant” 
to changes of IgG level (substitution) and there is no feed-
-back phenomenon observed in majority of HIGM.
Immunological tests
The immunoglobulins level in patients’ serum was 
measured with nephelometry (Dade-Behring Corporation 
Germany). 
The immunophenotype assay of mononuclear was per-
formed on venous blood after staining with monoclonal an-
tibody in double staining method. There were two methods 
of staining the mononuclear cells: one performed on whole 
blood followed with lysis of erythrocytes and the second 
performed on the mononuclear cells population (PBMC) 
isolated based on density gradient (Ficoll/Isopaque, Elkabe, 
Sweden). The set of fluorochrome conjugated monoclonal 
antibodies (IMK kit – Becton-Dickinson, Belgium) – anti 
CD3, CD4, CD8, CD45, CD14, CD19 was used for routi-
ne immunophenotype assay with whole blood method. The 
additional antibodies – anti-HLA-DR, TCR α/β, TCR γ/δ, 
NK cells, CD11a, CD18, CD40, CD154 (PharMingen/Bec-
ton-Dickinson, Belgium) FITC or PE or PerCP conjugated 
were used for immunophenotype assay on PBMC. These 
antibodies are used for patients with immunodeficiency. 
The inducible expression of CD154, CD40 was assayed on 
PBMC cultured for 4 hours in medium or in the presence of 
stimulators: PMA (50 ng/ml) (Sigma, Germany) and iono-
mycin (3 µg/ml) (Sigma). The mononuclear cells from heal-
thy person were cultured in parallel and use as control [4]. 
Flow cytometry assay
The cells stained with monoclonal antibodies according 
to manufacturer procedure, washed, suspended in PBS were 
assayed in flow cytometer (FACS Calibur, Becton-Dic-
kinson, Palo Alto, CA) after acquisition of 10 000 events 
from each tube. The isotype control was run in parallel. The 
analysis was performed on mononuclear cells (after lysis 
of erythrocytes from the whole blood) and on lymphocytes 
(PBMC and cultured cells) gated on FSC and SSC dot plot. 
The dot plot and histograms overlay were use for visualiza-
tion of results with the quadrant and histograms statistics.
There no molecular tests for CD40L gene performed.
Mitogen/antigen response of lymphocytes
Isolated PBMC were cultured in medium (RPMI1640) 
supplemented with 10% of foetal calf serum (FCS, Bio-
chrom, Germany), antibiotics in the presence of medium 
only, phytohaemagglutinin (PHA – 2.5 µg/ml) (Murex), 
monoclonal antibody against CD3 (CD3 – 1 µg/ml) (Immu-
notech, Germany) and pokeweed mitogen (PWM – stock 
dilution 1:1000) (Gibco, Germany) for 72 hrs in humid, 5% 
CO
2
 atmosphere in 37°C temperature. For the last 6 hrs the 
3H-thymidine (NEN, England) was added than the cells were 
harvested. Incorporation of 3H-Thymidine was measured in 
a liquid scintillation beta counter (Beckman Instruments). 
Stimulation index is a ratio between proliferation (assayed 
as cpm) of stimulated cells and non-stimulated cells.
Discussion
In HIGM syndrome the serum level of IgG, IgA and IgE 
immunoglobulins are markedly decreased or even absent. 
It is known that at diagnosis the serum level of IgM may 
be increased, normal or decreased [5-7]. The typical clini-
cal features of HIGM patients represent infections, mainly 
upper respiratory tract with different clinical course from 
severe, life threatening to mild. The presented 4 patients 
with diagnosis of HIGM syndrome reveal variety of clinical 
symptoms observed in HIGM. The 3 boys (case 1-3) repre-
sent the primary probable cases of HIGM whereas the girl 
(case 4) with late onset of HIGM represents probably the 
“secondary” form of HIGM. 
The HIGM diagnosis of case 1 was difficult because of 
normal level of serum IgM. Moreover, the clinical course 
including early onset, overlapped the diagnosis of HIGM 
with common variable immunodeficiency (CVID). The 
20
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5
0
IVIG substitution
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)
patient 4
IgA IgM IgG
azathioprine, high dose steroids
Fig. 2. The follow-up of IgG, IgA and IgM level in case 4. The 
assay was performed in every 3 months in a day of IgG substi-
tution before IVIG administration
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persistent neutropenia resistant to G-CSF correction and the 
results of immunological tests (CD154 assay) were indica-
ting the HIGM diagnosis (figure 3). However, in some cases 
of CVID the clinical course is severe and the expression of 
CD154 may be low [5] what possibly lead to misdiagnosis 
of HIGM. In our case the study of CD154 expression were 
performed at age 7 years what helped us to avoid the decre-
ase of CD154 observed in neonatal period or in transient hy-
Fig. 3. The flow cytometry assay of CD154 expression on CD3+ (T lymphocytes) cells. The peripheral blood mononuclear cells 
(PBMC) were activated with PMA and ionomycin for 4 hrs. The cells isolated from healthy person were run in parallel and used as 
control. The expression of CD154 was shown as histogram of gated population of CD3+ cells. The overlay of histogram unstimu-
lated and stimulated cells show the increase of fluorescence mean as expression of CD154. The comparison to control cells showed 
the lower expression in case 1 (only 24% of cells) and case 4 (whole population with lower MCF). The expression of stimulated 
cells from case 2 and case 3 was comparable to control cells (data not shown)
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pogammaglobulinemia of infants [5]. Taking into the consi-
deration the early onset, severe clinical course, neutropenia, 
results of CD154 tests and the response to IVIG therapy the 
diagnosis of HIGM seemed most probable in this case. 
The cases 2 and 3 represent mild course of disease what 
resulted in late diagnosis. The expression of CD154 was 
comparable to inducible expression of CD154 observed on 
lymphocytes from healthy person and the results of IVIG 
therapy were spectacular. The IVIG substitution was asso-
ciated with a sharp and immediate decrease of IgM level. 
However, the follow-up of immunoglobulins’ level showed 
IgM still above the normal value but below the high value 
observed at diagnosis, before the IVIG administration. The 
expected effect of IVIG in decrease of severity and frequen-
cy of infections was also noted.
The girl with DiGeorge’ syndrome (case 4), therapy-
-resistant thrombocytopenia, splenomegaly and episodes of 
neutropenia, showed the elevated IgM level at age 4 years 
despite of IVIG substitution. It suggested the diagnosis of 
the secondary or acquired form of HIGM. The induction 
of CD154 expression on T lymphocytes was lower than in 
control (figure 3). The immunosuppressants and steroids 
used for thrombocytopenia, thymic-growth factor used in 
DiGeorge’ syndrome supplementary therapy were consi-
dered as the factors inducing increase of IgM production 
(HIGM). There is no relation between the IgM level and 
IVIG substitution supported the hypothesis of secondary/
acquired form of HIGM. 
The low expression of CD154 observed as low percen-
tage of CD154 positive cells (case 1), low expression on 
stimulated cells (case 4) were associated with early symp-
toms and severe course of disease. The similar observations 
of severe course of infections in patients with present but 
low CD154 expression were noted [5, 7, 11]. These clinical 
features and low expression of CD154 are very difficult to 
discriminate between the severe form of CVID and HIGM. 
In these cases the molecular studies of CD154 gene muta-
tions are the only method to prove the clinical diagnosis 
of HIGM, in particular HIGM1 type [5]. The association 
of low or absent expression of CD154 with the increase of 
IgM is not so obvious and the high level of IgM was noted 
only in part of HIGM cases [11]. The lack of CD154 expres-
sion (HIGM1 type) is associated with mechanisms different 
than in other types of HIGM, includes the intrinsic T cell 
defect, lack of efficient delivery of activation signal from 
T to B lymphocytes. In patients with HIGM1 the persistent 
or cyclic neutropenia, resistant to G-CSF is frequent what 
facilitates the occurrence of severe and prolonged infections 
[7]. The therapy with IVIG and sulphonamides diminished 
the effect of persistent neutropenia, however, in some cases 
the neutropenia was clinically silent [7]. 
The coexistence of DiGeorge’ anomaly and HIGM 
syndrome is extremely rare or even described for the first 
time. The low expression of CD154 was observed when the 
level of IgM was high but this assay was performed for the 
first time. The explanation of elevated IgM level (HIGM) 
in this case is difficult and might include the different fac-
tors. There is some data indicating that high level of IgM 
might reflect chronic antigenic stimulation and normalised 
after appropriate therapy of infections [11]. In our case the 
level of IgM became high after the long period of severe, 
recurrent infections. However, the therapy with IVIG and 
steroids did not normalise IgM level. It suggests another 
mechanism involved in the regulation of IgM production in 
this case and the diagnosis of secondary/acquired form of 
HIGM was proposed. 
Presented cases of HIGM showed that screening for 
primary immunodeficiency including CD154 expression 
should be performed in patients presenting infections with 
severe clinical course, particularly recurrent pneumonias. 
Moreover, the screening for primary immunodeficiency sho-
uld include patients in older age than infants and small chil-
dren what may help to diagnose HIGM syndrome with mild 
clinical course. The therapy with IVIG resulted in normalisa-
tion of IgM level and decrease of the frequency and severity 
of infections. The early diagnosis followed with IVIG the-
rapy might be beneficial for patients in prophylaxis against 
infections and complications of these infections as a factor 
improving the general condition and life comfort of patients. 
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